Evidence map›Paper›PMID 33748741›Full record

ArticleInternational journal of pharmaceutics: X2021

Formulation development of itraconazole PEGylated nano-lipid carriers for pulmonary aspergillosis using hot-melt extrusion technology.

Gauri Shadambikar, Sushrut Marathe, Nan Ji, Mashan Almutairi, Suresh Bandari, Feng Zhang, Mahavir Chougule, Michael Repka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gauri ShadambikarDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Sushrut MaratheDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Nan JiDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Mashan AlmutairiDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Suresh BandariDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Feng ZhangCollege of Pharmacy, The University of Texas at Austin, TX 78712, USA.
Mahavir ChouguleDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.
Michael RepkaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary delivery is a promising alternative for the oral treatment of pulmonary aspergillosis. This study aimed to develop continuous and scalable itraconazole PEGylated nano-lipid carriers (ITZ-PEG-NLC) for inhalation delivery. The feasibility of preparing NLCs utilizing hot-melt extrusion (HME) coupled with probe sonication was investigated. The process parameters for HME and sonication were varied to optimize the formulation. ITZ-PEG-NLC (particle size, 101.20 ± 1.69 nm; polydispersity index, 0.26 ± 0.01) was successfully formulated. The drug entrapment efficiency of ITZ-PEG-NLC was 97.28 ± 0.50%. Transmission electron microscopy was used to characterize the shape of the particles. The developed formulations were evaluated for their aerodynamic properties for pulmonary delivery. The lung deposition of ITZ-PEG-NLC was determined using an Anderson Cascade Impactor and Philips Respironics Sami the Seal Nebulizer Compressor.

Indexed as

Hot-melt extrusionInhalationItraconazoleNanostructured lipid carriersPEGylationPulmonary drug delivery

Identifiers

PMID33748741
PMCPMC7973123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.